Intra-Cellular Therapies Inc (ITCI) USD0.0001
2.48%- This stock can be held in a
Stocks and Shares ISASell:$76.16
Buy:$76.27
Change:
$2.41
(3.07%)
$2.41
(3.07%)Prices delayed by at least 15 minutes
Sell:$76.16
Buy:$76.27
Change:$2.41
(3.07%)
$2.41
(3.07%)Prices delayed by at least 15 minutes
Director deals
Listed below are trades carried out by directors and other individuals which are required to be notified to the market.
Recent deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 24 June 2024 | Rory B RiggsIndependent Director | Sell Option/Award related | 4,462 | $75.57 | $337,193.34 | 116,600 |
| 18 June 2024 | Robert L Van NostrandIndependent Director | Sell Option/Award related | 8,891 | $75.71 | $673,137.61 | 20,799 |
| 18 June 2024 | Robert L Van NostrandIndependent Director | Sell Option/Award related | 11,109 | $76.07 | $845,061.63 | 9,690 |
| 11 March 2024 | Sharon MatesChairman/CEO | Sell Tax related | 14,541 | $64.80 | $942,256.80 | 1,056,333 |
| 11 March 2024 | Sharon MatesChairman/CEO | Sell Tax related | 4,128 | $65.90 | $272,035.20 | 1,052,205 |
| 11 March 2024 | Sharon MatesChairman/CEO | Sell Tax related | 1,590 | $66.81 | $106,227.90 | 1,050,615 |
| 11 March 2024 | Sharon MatesChairman/CEO | Sell Tax related | 306 | $67.33 | $20,602.98 | 1,050,309 |
| 11 March 2024 | Mark NeumannChief Level Officer | Sell Tax related | 4,303 | $65.11 | $280,168.33 | 32,742 |
| 11 March 2024 | Mark NeumannChief Level Officer | Sell Tax related | 1,729 | $65.92 | $113,975.68 | 31,013 |
| 11 March 2024 | Mark NeumannChief Level Officer | Sell Tax related | 1,313 | $66.86 | $87,787.18 | 29,700 |
5 most significant deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 16 January 2024 | Sharon MatesChairman/CEO | Sell Option/Award related | 65,979 | $67.25 | $4,437,087.75 | 1,056,191 |
| 18 January 2024 | Sharon MatesChairman/CEO | Sell Option/Award related | 67,597 | $65.19 | $4,406,648.43 | 1,050,629 |
| 7 August 2023 | Mark NeumannChief Level Officer | Sell Option/Award related | 55,300 | $58.79 | $3,251,087.00 | 45,339 |
| 2 January 2024 | Suresh K. DurgamOther Level A | Sell Option/Award related | 37,427 | $70.41 | $2,635,235.07 | 24,855 |
| 19 September 2023 | Sharon MatesChairman/CEO | Sell Regular sell transaction (market) | 44,413 | $54.17 | $2,405,852.21 | 1,050,309 |
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Director deal information provided by Factset.